+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Xadago"

CNS Therapeutics - Global Strategic Business Report - Product Thumbnail Image

CNS Therapeutics - Global Strategic Business Report

  • Report
  • March 2024
  • 898 Pages
  • Global
From
From
From
Global Parkinson's Drug Market & Clinical Trial Insight 2025 - Product Thumbnail Image

Global Parkinson's Drug Market & Clinical Trial Insight 2025

  • Clinical Trials
  • January 2020
  • 500 Pages
  • Global
From
Xadago - Product Thumbnail Image

Xadago

  • Report
  • June 2018
  • 15 Pages
  • Global
From
  • 5 Results (Page 1 of 1)
Loading Indicator

Xadago is a market within the context of Central Nervous System (CNS) drugs. It is a type of drug used to treat Parkinson's disease, a neurological disorder that affects movement. Xadago is a monoamine oxidase type B (MAO-B) inhibitor, which works by blocking the breakdown of dopamine in the brain. This helps to improve the symptoms of Parkinson's disease, such as tremors, stiffness, and difficulty with movement. Xadago is also used to treat depression and anxiety. The Xadago market is made up of a variety of companies, including Merck, Teva Pharmaceuticals, and Lundbeck. These companies produce and distribute Xadago, as well as other CNS drugs. They also provide support and resources to patients and healthcare professionals. Additionally, there are a number of research organizations and clinical trials that are dedicated to studying the effects of Xadago and other CNS drugs. Show Less Read more